-
What are the new cancer treatments approved in the UK?
The NHS has recently approved two new cancer treatments: capivasertib, which targets advanced breast cancer, and erdafitinib, aimed at treating FGFR-altered urothelial cancer. These approvals are expected to enhance treatment options for patients in England and Wales.
-
How do capivasertib and erdafitinib work?
Capivasertib is a targeted therapy that inhibits the AKT pathway, which is often activated in breast cancer cells, thereby slowing down tumor growth. Erdafitinib, on the other hand, targets FGFR (fibroblast growth factor receptor) alterations, which are common in certain bladder cancers, helping to block signals that promote cancer cell proliferation.
-
What impact will these treatments have on patient outcomes?
Experts believe that the approval of capivasertib and erdafitinib will significantly improve patient outcomes by providing more effective treatment options. Capivasertib is seen as a 'landmark moment' for breast cancer therapy, while erdafitinib is expected to make a 'significant difference' for bladder cancer patients, offering new hope for those with limited options.
-
Are there any side effects associated with these new drugs?
Like all medications, capivasertib and erdafitinib may have side effects. Common side effects can include fatigue, nausea, and changes in liver function. However, the specific side effects can vary based on individual patient factors and the combination of therapies used. It's essential for patients to discuss potential side effects with their healthcare providers.
-
Why is timely access to these treatments important?
Timely access to innovative cancer treatments is crucial as delays can lead to disease progression and reduced treatment effectiveness. The recent approvals reflect a broader trend in cancer care towards personalized therapies, emphasizing the need for faster drug approvals to ensure patients receive the best possible care without unnecessary delays.